| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $341K | — | -43.0% |
| SG&A Expense | $1.4M | — | -11.3% |
| Operating Income | -$1.7M | — | +21.2% |
| Net Income | -$1.7M | — | +21.8% |
| EPS (Basic) | -$0.62 | — | -463.6% |
| EPS (Diluted) | -$0.62 | — | -463.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $56K | +16.3% | — |
| Total Assets | $9.5M | +24.1% | — |
| Current Liabilities | $2.5M | +4.4% | +1.3% |
| Total Liabilities | $2.5M | +4.4% | +1.3% |
| Stockholders' Equity | $7.0M | +33.1% | +203.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.4M | — | +31.4% |
| Financing Cash Flow | $3.1M | — | +3.9% |